Pomaglumetad methionil hydrochloride

Research use only, not for human use.

Pomaglumetad methionine hydrochloride (LY2140023 hydrochloride) is a methionine prodrug of LY404039 with oral activity.

Pomaglumetad methionil hydrochloride (LY2140023 hydrochloride) is an orally active, methionine prodrug of the selective mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil hydrochloride has the potential for schizophrenia research.

Pomaglumetad methionil (LY2140023) is a high-affinity peptide transporter 1 (PEPT1) substrate with a Km value of ~30 μM.LY2140023 is active against [14C]Gly-Sar with an IC50 value of 0.018 mM.

Pomaglumetad methionil (LY2140023; orally; 3-300 mg/kg; once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) .Animal Model:Male Fischer rats (approximately 250 g) Dosage:3 mg/kg, 10 mg/kg, and 300 mg/kg Administration:Orally; once daily for 7 days Result:Dose-dependent increased the levels of the dopamine metabolites DOPAC and HVA.

——

Neuroscience

GluR

GluR

——

——

635318-26-2

402.87

C12H19ClN2O7S2

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (62.05 mM; Ultrasonic )

Cl.[H][C@@]12[C@@H](C(O)=O)[C@]1([H])S(=O)(=O)C[C@@]2(NC(=O)[C@@H](N)CCSC)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years